N. B. Leighl

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Martin Reck, Joachim von Pawel, Petr Zatloukal et al. · Annals of Oncology · 2010 · 640 citations · Full text

First-line Therapy, Oncology, Overall Survival +8

Biomarkers That Currently Affect Clinical Practice: EGFR, ALK, MET, KRAS

Mark Vincent, M. Sara Kuruvilla, N. B. Leighl et al. · Current Oncology · 2012 · 56 citations · Full text

Clinical Endpoint, Pathology, Tumor Biology +19

Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC).

Heather A. Wakelee, Suzanne E. Dahlberg, S.M. Keller et al. · Journal of Clinical Oncology · 2011 · 32 citations

Preclinical Therapeutics, Surgical Oncology, Early Stage Nsclc +20

A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results

V. Papadimitrakopoulou, G. R. Blumenschein, N. B. Leighl et al. · Journal of Clinical Oncology · 2008 · 31 citations

1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

N. B. Leighl, Catherine A. Shu, Anna Minchom et al. · Annals of Oncology · 2021 · 31 citations

Amivantamab Monotherapy, Post-osimertinib Egfr-mutant Nsclc, Medicine +8